🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉LBA4513: Dr #VitalyMargulis presenting padeliporfin vascular targeted photodynamic therapy (VTP) for low grade UTUC from ph3 #ENLIGHTED 🩺Clinical implications: - #ENLIGHTED shows #VTP has early efficacy and safety supporting accrual

ENLIGHTED phase 3: Padeliporfin VTP in Low-Grade UTUC #ASCO25 Vitaly Margulis OncoAlert 🟠 CR rate: 73%, PR 13.5%, ORR 86.5% 🟠 Recurrence: 10.8% | Progression: 2.7% 🟠 Grade 1–2 TEAEs were transient → hematuria (14%), flank pain (10%), procedural pain (6.4%) 🟠 Grade 3 SAEs

Finally, we have the primary results of the #CheckMate901 trial at #ASCO25. Unfortunately, it missed statistical significance — but the trend toward improved OS is clear, and the quality of responses in responders is remarkable. We need biomarkers beyond PD-L1 to identify these

Privilege to be one of the co-authors! CheckMate 901: NIVO+IPI vs Gem-Carbo in cisplatin-ineligible mUC. ✔ OS at 5 years: 23.0% vs 14.4% ✔ mOS: 19.1 vs 13.2 months (HR: 0.79) ✔ Durable responses even off-treatment But primary endpoint not met for PD-L1 ≥1% Presented by

🌟🎓👏👏👏Clear and data-rich presentation by Michiel Simon Van Der Heijden CheckMate 901: NIVO+IPI vs gem-carbo in cis-ineligible mUC #ASCO25 OncoAlert 🟠 mOS: 19.1 vs 13.2 mo | HR 0.79, P = 0.0245 (not statistically significant) 🟠 36-mo OS rate: 29.6% vs 19.3% 🟠 36-mo PFS

⚡️Oral Abstract⚡️ CheckMate-901: Nivo + Ipi vs Gem + Carbo in 1L mUC UroToday.com #ASCO25 📌OS: HR 0.79, 98.27% CI, 0.61–1.01 📌PFS: HR 0.90, 95% CI 0.72-1.12 📌ORR: 35.3% vs 38.8% Negative trial, but OS rates at 60 months: 23.0% vs 14.4%

📢 #ASCO25 | High-risk penile cancer Ph. II | Adjuvant cis + Paclitaxel vs cis + 5-FU: mPFS 36 m vs 12 m; mOS 37 m vs 21 m (NS). ≥G3 GI & heme AEs ↑ with 5F2R; sensory neuropathy & LFT ↑ with pacli; QoL similar. First randomized data in this setting. by Aditya Dhanawat et al.

🗣️Prostate Rapid Oral Abstract #ASCO25 👉Abst5014: Dr #EricHuttenlocherBent presenting intensified ADT+ARPI + SBRT in oligomet PCA on #METACURE Cohort B2 (10 pts) ⚡️metastasis-directed SBRT + 10mo hormonal therapy 💊ADT + apalutamide + abiraterone (ADT+APA+AAP)

Excited to share the first results from our ⁦Johnson & Johnson Innovation⁩ new KLK2xCD3 investigational agent called pasritamig, a first-in-class, Bispecific T-Cell Engager Targeting Human Kallikrein 2 (KLK2) in #mCRPC. #MyCompany ascopubs.org/doi/10.1200/JC…

Targeting B7-H3 in post ARPI refractory mCRPC pays off with a new ADC: DB-1311/BNT324. ORR of 42% and 6 mo PFS rate of 68% warrants future controlled trials! Abstract 5015 at #ASCO25 #MedIQASCO25 The PCCTC

📢 #ASCO25 | DB-1311/BNT324 B7H3 ADC in Heavily Pretreated CRPC: Phase I/II in CRPC (n=65) shows ORR 27.9%, DCR 95.3%; median rPFS 8.3 m; manageable safety (G≥3 TRAEs 40%). by Andrew Parsonson et al. Full abstract → [shorturl.at/meFe4] ASCO The ASCO Post Journal of Clinical Oncology

🧬 Pasritamig (KLK2xCD3 bispecific) in mCRPC: ⚡ First-in-class T-cell engager targeting KLK2 🛡️ Well tolerated – no Gr ≥3 CRS, no ICANS, no discontinuations 🧪 Early signs of PSA and radiographic response 🏥 Outpatient-friendly profile 📢 Proof-of-concept achieved → Phase

📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from Gustave Roussy et al. Full abstract → [shorturl.at/meFe4] ASCO The ASCO Post Journal of Clinical Oncology

Listen to Stephen Freedland, MD and Axel S. Merseburger discuss personalised medicine, molecular testing, and improving patient quality of life in #mCRPC with NEW podcast episodes #ProstateCancer #Oncology #Podcast #MedX ow.ly/bTEP50W2oIr

🎥 Die ersten Highlights vom #ASCO25 sind online! 👉 Kostenlos & on demand auf onkowissenTV. Verpasse nicht die neuesten Insights aus der Onkologie! 🔗 onkowissen.tv/beitraege/asco… #Onkologie #ASCO2025 #onkowissenTV Jozefina Casuscelli Christoffer.Gebhardt Peter J. Goebell Prof. Dr. med. Diana Lüftner Axel S. Merseburger

Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant #ProstateCancer. Presentation by Alan H Bryce City of Hope. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/43Fdo2n ASCO

#ASCO25

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

🌟Radioligand Therapies Unplugged at #ASCO25 [177Lu]Lu-PSMA-617 as ADT-sparing therapy in oHSPC: randomized phase 2 trial OncoAlert Advanced Prostate Cancer Consensus Conference 🔵 mPFS: NR vs 5 mo | HR 0.07 🔵 PSA change: -91% vs +125% 🔵 CR in 21% 🔵 AEs mostly G1: dry mouth, fatigue, cytopenias 👉 Safe,

PSMAddition trial met its primary endpoint and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer ESMO - Eur. Oncology #ASCO25 novartis.com/news/media-rel…